Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 19 Issue 5, May 2020

Artificial intelligence in drug design, inspired by the Perspective on p353.

Cover design: Susanne Harris. Original structure image from Kheng Ho Toh/Alamy Stock Photo.


Top of page ⤴

News & Analysis

Top of page ⤴

Research Highlights

Top of page ⤴


  • Naturally occurring cationic host defence peptides, also known as antimicrobial peptides, can control infections by their direct microbicidal properties and by modulating the host’s immune responses. In addition, certain cationic host defence peptides can resolve harmful inflammation. Here, Mookherjee et al. assess the emerging potential to therapeutically harness these peptides to treat infectious diseases, chronic inflammatory disorders and wound healing, highlighting current preclinical studies and clinical trials.

    • Neeloffer Mookherjee
    • Marilyn A. Anderson
    • Donald J. Davidson
    Review Article
  • Existing antiplatelet and anticoagulant agents for the prevention and treatment of thrombosis are associated with bleeding risk. Here, Mackman and colleagues provide an overview of haemostasis and thrombosis and assess the advantages and limitations of existing antithrombotics. The emerging antithrombotic targets and agents in development as well as the associated challenges are discussed.

    • Nigel Mackman
    • Wolfgang Bergmeier
    • Jeffrey I. Weitz
    Review Article
Top of page ⤴


  • Artificial intelligence (AI) tools are increasingly being applied in drug discovery. This article presents the views of a group of international experts on the ‘grand challenges’ in small-molecule drug discovery with AI, including obtaining appropriate data sets, generating new hypotheses, optimizing in a multi-objective manner, reducing cycle times and changing the research culture.

    • Petra Schneider
    • W. Patrick Walters
    • Gisbert Schneider

    Innovations In:

Top of page ⤴


Quick links